Wide Ranks

ANRO

Alto Neuroscience, Inc.

4.28

Top Statistics
Market Cap 115 M Forward PE -1.49 Revenue Growth 0.00 %
Current Ratio 13.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.8180 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 181 M Total Cash Per Share 6.74 Total Debt 14 M
Total Debt To Equity 8.95 Current Ratio 13.10 Book Value Per Share 6.12
All Measures
Short Ratio 331.00 % Message Board Id finmb_1675972978 Shares Short Prior Month 5 M
Return On Equity -0.5672 City Los Altos Uuid de8f86a8-e9a0-3331-96ee-f60530d2d3c7
Previous Close 4.33 First Trade Date Epoch Utc 1 B Book Value 6.12
Total Debt 14 M Volume 120463 Price To Book 0.6993
Fifty Two Week Low 3.61 Total Cash Per Share 6.74 Shares Short Previous Month Date 1 B
Target Median Price 10.00 Max Age 86400 Recommendation Mean 1.33
Sand P52 Week Change 0.3133 Target Mean Price 11.52 Net Income To Common -57447000
Ask 4.32 Short Percent Of Float 0.2194 Implied Shares Outstanding 26 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 344220
Average Volume10days 344220 Total Cash 181 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0751 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 4.33 Target Low Price 4.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.21 Open 4.36
Free Cashflow -35431000 State CA Dividend Yield 0.00 %
Return On Assets -0.3236 Time Zone Short Name EST Trailing Eps -2.38
Day Low 4.28 Address1 369 South San Antonio Road Shares Outstanding 26 M
Price Hint 4 Target High Price 17.00 Website https://www.altoneuroscience.com
52 Week Change -0.7932 Average Volume 780184 Forward Eps -2.87
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1296.50 %
Is_sp_500 False Regular Market Day High 4.50 Profit Margins 0.00 %
Debt To Equity 8.95 Fifty Two Week High 24.00 Day High 4.50
Shares Short 4 M Regular Market Open 4.36 Industry Key biotechnology
Bid 4.30 Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1728 Operating Cashflow -45927000 Currency USD
Time Zone Full Name America/New_York Market Cap 115 M Is_nasdaq_100 False
Zip 94022 Quote Type EQUITY Industry Biotechnology
Regular Market Day Low 4.28 Held Percent Institutions 0.9170 Current Price 4.28
Enterprise To Ebitda 0.8180 Financial Currency USD Current Ratio 13.10
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 19 M Two Hundred Day Average 11.90 Enterprise Value -51505960
Forward PE -1.49 Regular Market Volume 120463 Ebitda -62934000
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD.

In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient.

The company was incorporated in 2019 and is headquartered in Los Altos, California.